ORPHA:99949
Charcot-Marie-Tooth disease type 4C
Also known as: CMT4C
Publications
250
74.9th percentile
Trials
0
Interventional, condition-specific
Researchers
1,208
Distinct authors in sample
Gene link
SH3TC2
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A form of Charcot-Marie-Tooth disease type 4 characterized by childhood or adolescent-onset of a relatively mild, demyelinating sensorimotor that contrasts with a severe, rapidly progressing, early-onset scoliosis, and the typical CMT (i.e. distal muscle weakness and atrophy, sensory loss, absence of deep tendon reflexes, and often foot deformity). A wide spectrum of nerve conduction velocities are observed and cranial nerve involvement and kyphoscoliosis have also been reported.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011113
- MeSH:C535423
- OMIM:601596
- UMLS:C1866636
- NCIT:C129864
Additional Mondo synonyms (2)
Charcot-Marie-Tooth disease type 4 caused by mutation in SH3TC2 · SH3TC2 Charcot-Marie-Tooth disease type 4
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Definitive — SH3TC2
- LiteraturePresent
250 matched papers (159 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 42 for broader category Charcot-Marie-Tooth disease
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (SH3TC2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
250
250 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
250 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
159 in the last 10 years · high confidence · 74.9th percentile (publications denominator)
Phrase hits: 250 · MeSH hits: 2
Who's working on it?
1,208
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Reilly MM18 papers · 2025
National Hospital for Neurology and Neurosurgery, University College London, London, United Kingdom.
Papers in Europe PMC - 02Shy ME18 papers · 2025
Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Papers in Europe PMC - 03Pareyson D15 papers · 2025
Departments of Neurology, IRCCS Foundation, Carlo Besta Neurological Institute, Milan, Italy.
Papers in Europe PMC - 04Burns J11 papers · 2025
Departments of Neurology, University of Sydney & Children's Hospital, Sydney, Australia.
Papers in Europe PMC - 05Finkel RS9 papers · 2026
Departments of Neurology, Nemours Children's Hospital, Orlando, Florida, USA.
Papers in Europe PMC - 06Herrmann DN8 papers · 2023
Departments of Neurology, University of Rochester, Rochester, New York, USA.
Papers in Europe PMC - 07Kagiava A8 papers · 2026
Neuroscience Laboratory, The Cyprus Institute of Neurology and Genetics and Cyprus School of Molecular Medicine, Nicosia, Cyprus.
Papers in Europe PMC - 08Moroni I8 papers · 2023
Departments of Neurology, IRCCS Foundation, Carlo Besta Neurological Institute, Milan, Italy.
Papers in Europe PMC - 09Senderek J8 papers · 2026
Department of Human Genetics, Aachen University of Technology, Aachen, Germany. jsenderek@ukaachen.de
Papers in Europe PMC - 10Chrast R7 papers · 2019
Department of Neuroscience, Karolinska Institutet, 171 65 Stockholm, Sweden. roman.chrast@ki.se.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial. 42 trials are registered for Charcot-Marie-Tooth disease, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
42 interventional trials matched Charcot-Marie-Tooth disease, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: Charcot-Marie-Tooth disease
42
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07140614·RECRUITING·A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
Conditions: Charcot-Marie-Tooth Disease, Type 1A·Matched via name phrase
- NCT07726043·RECRUITING·Clinical Trial Evaluating the Impact of an Intensive Rehabilitation Program Combined With Tendon Vibratory Stimulation on Functional Balance in Individuals With Charcot-Marie-Tooth Disease Type 1A
Conditions: Charcot-Marie-Tooth Disease Type 1A·Matched via name phrase
- NCT07226297·ENROLLING BY INVITATION·Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)
Conditions: Charcot-Marie-Tooth Disease Type 2D·Matched via name phrase
- NCT07447557·RECRUITING·Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)
Conditions: Charcot-Marie-Tooth Disease Type 4J·Matched via name phrase
- NCT07136844·RECRUITING·Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Conditions: Neuromuscular Diseases · Obesity (Disorder) · Myotonic Dystrophy 1 · Myasthenic Syndrome·Matched via name phrase
- NCT06881979·RECRUITING·High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project
Conditions: Amyotrophic Lateral Sclerosis · Chronic Inflammatory Demyelinating Neuropathy · Charcot-Marie-Tooth Disease·Matched via name phrase
- NCT06708468·RECRUITING·Personalized Training for People With Rare Neuromuscular Disorders
Conditions: Neuromuscular Diseases (NMD) · Charcot Marie Tooth Disease (CMT) · Facioscapulohumeral Muscular Dystrophy · Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT07478172·RECRUITING·Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Conditions: Neuromuscular Diseases (NMD) · Amyotrophic Lateral Sclerosis · Myasthenia Gravis · Lambert-eaton Myasthenic Syndrome·Matched via name phrase
- NCT07188415·RECRUITING·CMT Gait, Mobility, Balance - AOFAS Grant
Conditions: Charcot Marie Tooth Disease (CMT)·Matched via name phrase
- NCT07152197·RECRUITING·Effects of Resistance Exercises in Hereditary Sensory-Motor Neuropathy (Charcot-Marie-Tooth Disease)
Conditions: Polyneuropathy · Charcot Marie Tooth Disease (CMT)·Matched via name phrase
- NCT06328712·RECRUITING·Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)
Conditions: Charcot-Marie-Tooth Disease Type 1A·Matched via name phrase
- NCT07049588·RECRUITING·Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease
Conditions: Charcot-Marie-Tooth Disease Type 1A·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05902351·RECRUITING·Natural History Study for Charcot Marie Tooth Disease
Conditions: Charcot-Marie-Tooth Disease · Charcot-Marie-Tooth · Charcot-Marie-Tooth Disease, Type IA · Charcot-Marie-Tooth Disease Type 2A·Matched via name + MeSH
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Charcot-Marie-Tooth disease type 4C" OR "CMT4C" OR "Charcot-Marie-Tooth disease type 4 caused by mutation in SH3TC2" OR "SH3TC2 Charcot-Marie-Tooth disease type 4"
MeSH descriptor terms unioned into the query: Charcot-Marie-Tooth disease, Type 4C
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Charcot-Marie-Tooth disease type 4C" OR "CMT4C" OR "Charcot-Marie-Tooth disease type 4 caused by mutation in SH3TC2" OR "SH3TC2 Charcot-Marie-Tooth disease type 4" OR "Charcot-Marie-Tooth disease, Type 4C" OR "SH3TC2" OR "Charcot-Marie-Tooth disease type 4"
Recall-expansion terms: SH3TC2, Charcot-Marie-Tooth disease type 4
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Charcot-Marie-Tooth disease"
Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T06:45:19.230Z